A Study of LY3502970 in Healthy Participants
1상
완료
NCT03929744
| 대상 질환 | Healthy |
|---|
| 임상 단계 | 1상 |
|---|
| 스폰서 | Eli Lilly and Company |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 133 명 |
|---|
| 중재(약물) | LY3502970, Atorvastatin, Simvastatin, Midazolam |
|---|
| 시작일 | 2019년 6월 12일 |
|---|
| 완료일 | 2020년 11월 2일 |
|---|
| 결과 공개일 | 2026년 7월 10일 |
|---|
요약
The main purposes of this study are to determine: * The safety of LY3502970 and any side effects that might be associated with it. * How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it. This study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition.
Parts A and B: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
Baseline through Follow-up (up to Day 42) · Participants
| Part A Placebo | 0 Participants |
|---|
| Part A 0.3 mg LY3502970 | 0 Participants |
|---|
| Part A 1 mg LY3502970 | 0 Participants |
|---|
| Part A 3 mg LY3502970 | 0 Participants |
|---|
| Part A 6 mg LY3502970 | 0 Participants |
|---|
| Part B Placebo | 0 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.